American Trust Has $687,000 Position in Novo Nordisk A/S (NYSE:NVO)

American Trust reduced its position in shares of Novo Nordisk A/S (NYSE:NVO) by 12.8% in the 1st quarter, Holdings Channel reports. The firm owned 5,350 shares of the company’s stock after selling 786 shares during the period. American Trust’s holdings in Novo Nordisk A/S were worth $687,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of NVO. Cypress Asset Management Inc. TX raised its position in Novo Nordisk A/S by 1.2% during the 1st quarter. Cypress Asset Management Inc. TX now owns 17,916 shares of the company’s stock valued at $2,392,000 after purchasing an additional 221 shares during the last quarter. Hamilton Wealth LLC boosted its holdings in shares of Novo Nordisk A/S by 102.9% in the first quarter. Hamilton Wealth LLC now owns 63,856 shares of the company’s stock valued at $8,199,000 after purchasing an additional 32,382 shares during the period. Pathway Financial Advisers LLC purchased a new position in shares of Novo Nordisk A/S in the 1st quarter valued at $34,000. Soltis Investment Advisors LLC purchased a new stake in Novo Nordisk A/S during the 1st quarter worth approximately $208,000. Finally, Alexander Labrunerie & CO. Inc. purchased a new position in shares of Novo Nordisk A/S during the 1st quarter valued at approximately $1,446,000. Institutional investors own 11.54% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently weighed in on NVO. BMO Capital Markets reissued an “outperform” rating and issued a $163.00 price target on shares of Novo Nordisk A/S in a research note on Tuesday, June 25th. Argus raised their price objective on shares of Novo Nordisk A/S from $125.00 to $160.00 and gave the company a “buy” rating in a research report on Monday, June 10th. The Goldman Sachs Group initiated coverage on Novo Nordisk A/S in a report on Thursday, May 30th. They set a “buy” rating and a $156.00 target price on the stock. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Monday, July 1st. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $145.67.

Novo Nordisk A/S Trading Down 3.8 %

Shares of Novo Nordisk A/S stock traded down $4.97 during trading on Friday, hitting $127.49. The company’s stock had a trading volume of 4,774,033 shares, compared to its average volume of 3,918,008. Novo Nordisk A/S has a 52 week low of $78.19 and a 52 week high of $148.15. The company has a debt-to-equity ratio of 0.17, a current ratio of 0.70 and a quick ratio of 0.50. The stock has a 50-day moving average price of $138.21 and a two-hundred day moving average price of $129.20. The stock has a market cap of $572.12 billion, a price-to-earnings ratio of 43.96, a price-to-earnings-growth ratio of 1.33 and a beta of 0.41.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Thursday, May 2nd. The company reported $0.83 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.77 by $0.06. Novo Nordisk A/S had a net margin of 36.56% and a return on equity of 91.70%. The company had revenue of $9.52 billion for the quarter, compared to analyst estimates of $9.23 billion. Equities research analysts anticipate that Novo Nordisk A/S will post 3.38 EPS for the current fiscal year.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.